Recombinant Human NDUFAB1, N-His

Description of Recombinant Human NDUFAB1, N-His

Introduction

Recombinant Human NDUFAB1, N-His is a protein that plays a crucial role in the function of mitochondria, the powerhouse of the cell. This protein is encoded by the NDUFAB1 gene and is involved in the assembly and stabilization of mitochondrial respiratory chain complex I. Mutations in this gene have been linked to various mitochondrial disorders, making it a potential drug target for treating these conditions. In this article, we will explore the structure, activity, and potential applications of Recombinant Human NDUFAB1, N-His.

Structure of Recombinant Human NDUFAB1, N-His

The NDUFAB1 gene encodes for a protein of 199 amino acids, with a molecular weight of 22 kDa. The protein contains a histidine tag at the N-terminus, which allows for easy purification and detection. The crystal structure of Recombinant Human NDUFAB1, N-His has been determined, revealing a trimeric complex with three identical subunits. Each subunit consists of four alpha-helices and four beta-strands, forming a barrel-like structure. The active site of the protein is located at the interface between the three subunits, where it binds to the NADH cofactor.

Activity of Recombinant Human NDUFAB1, N-His

Recombinant Human NDUFAB1, N-His is a crucial component of mitochondrial complex I, also known as NADH:ubiquinone oxidoreductase. This enzyme complex is responsible for the first step in the electron transport chain, which is essential for the production of ATP, the energy currency of the cell. NDUFAB1 is involved in the assembly and stabilization of complex I, ensuring its proper functioning. It also plays a role in the transfer of electrons from NADH to ubiquinone, a process that generates a proton gradient across the mitochondrial membrane, which is necessary for ATP production.

Applications of Recombinant Human NDUFAB1, N-His

Mutations in the NDUFAB1 gene have been linked to various mitochondrial disorders, such as Leigh syndrome and mitochondrial encephalomyopathy. These conditions are characterized by defects in the electron transport chain, leading to impaired ATP production and energy deficiency. As a result, patients experience a wide range of symptoms, including muscle weakness, neurological problems, and developmental delays. Recombinant Human NDUFAB1, N-His has shown potential as a therapeutic target for these disorders. By restoring the function of complex I, it could potentially improve energy production and alleviate symptoms.

In addition to its potential in treating mitochondrial disorders, Recombinant Human NDUFAB1, N-His has also been studied for its role in cancer. Recent studies have shown that this protein is overexpressed in various types of cancer, including breast, lung, and colon cancer. It has been proposed that targeting NDUFAB1 could disrupt the energy metabolism of cancer cells, leading to their death. However, further research is needed to fully understand the potential of Recombinant Human NDUFAB1, N-His as a therapeutic target for cancer.

Conclusion

Recombinant Human NDUFAB1, N-His is a crucial protein involved in the function of mitochondrial complex I. Its structure and activity have been extensively studied, and it has shown potential as a drug target for treating mitochondrial disorders and cancer. With further research, this protein could potentially lead to the development of new treatments for these conditions.